|
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2.375 USD | +0.21% |
|
-0.21% | +31.94% |
| 13/05 | Protalix BioTherapeutics, Inc., Q1 2026 Earnings Call, May 13, 2026 | |
| 13/05 | Protalix BioTherapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 | CI |
Main competitors
| Consensus | Analysts' target price evolution (4 months) | Analysts' recommendations evolution (4 months) | Financial estimates divergence | Analysts' Target price divergence | Average Target P. | Objective/dr gap | Nbr of analysts | ||
|---|---|---|---|---|---|---|---|---|---|
 | - | 11 | +364.14% | 2 | |||||
| 1,270.37 | +7.13% | 27 | ||||||
| 270.59 | +4.37% | 22 | ||||||
| 266.89 | +3.88% | 28 | ||||||
| 361.17 | +3.34% | 18 | ||||||
| 153.66 | -1.65% | 21 | ||||||
| 212.16 | +25.65% | 22 | ||||||
| 317.2 | -0.97% | 24 | ||||||
| 356.69 | -3.99% | 29 | ||||||
| 157.56 | +20.4% | 27 | ||||||
| 28.75 | +14.95% | 26 | ||||||
| 62.96 | +2.35% | 24 | ||||||
| 554.91 | +17.3% | 23 | ||||||
| 95.6 | +25.2% | 22 | ||||||
| 21.39 | +12.26% | 20 | ||||||
| 9,853.33 | +36.62% | 15 | ||||||
| 6,156.44 | +11.83% | 16 | ||||||
| 80.52 | +46.64% | 15 | ||||||
| 54.92 | +18.87% | 18 | ||||||
| Average | 1,067.69 | +32.02% | 21 | ||||||
| Weighted average by Cap. | 713.04 | +8.31% | 24 |
- Stock Market
- Stocks
- PLX Stock
- Sector Protalix BioTherapeutics, Inc.
- Sector consensus
Select your edition
All financial news and data tailored to specific country editions
